Advertisement

Topics

Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine

08:30 EDT 17 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of p...

Other Sources for this Article

Merck
Media:
Pamela Eisele, 267-305-3558
or
Skip Irvine, 267-305-0338
or
Investors:
Teri Loxam, 908-740-1986
or
Michael DeCarbo, 908-740-1807

NEXT ARTICLE

More From BioPortfolio on "Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...